Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors

Journal of Neuro-Oncology

Volumn 65, Issue 1, 2003, Pages 27-35

  Sampson, John H ^a   Akabani, Gamal ^b   Archer, Gary E ^b   Bigner, Darell D ^b   Berger, Mitchel S ^c   Friedman, Allan H ^b   Friedman, Henry S ^b   Herndon II, James E ^b   Kunwar, Sandeep ^c   Marcus, Steve ^b   McLendon, Roger E ^b   Paolino, Alison ^b   Penne, Kara ^b   Provenzale, James ^b   Quinn, Jennifer ^b   Reardon, David A ^b   Rich, Jeremy ^b   Stenzel, Timothy ^b   Tourt Uhlig, S ^b   Wikstrand, Carol ^b   Wong, Terence ^b   Williams, Roger ^d   Yuan, Fan ^b   Zalutsky, Michael R ^b   Pastan, Ira ^e   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IVAX Corporation   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brain neoplasms; Convection enhanced delivery; Immunotoxin

Indexed keywords

ANTIBODY; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID DERIVATIVE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR I 125; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY LMB 1; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN 38; PSEUDOMONAS EXOTOXIN MONOCLONAL ANTIBODY OVB3 CONJUGATE; RECOMBINANT PROTEIN; RECOMBINANT TOXIN; TP 38; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

BACTERIUM MUTANT; BLOOD TOXICITY; BRAIN HEMORRHAGE; BRAIN TUMOR; BREAST CANCER; CANCER SURVIVAL; CATHETER; CHIMERA; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG INFUSION; FATIGUE; GENETIC ENGINEERING; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMIANOPIA; HEMIPARESIS; HUMAN; HYGROMA; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; LIGAND BINDING; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MOTOR DYSFUNCTION; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; RADIOGRAPHY; REVIEW; SEIZURE; SPEECH DISORDER; T CELL LYMPHOMA;

ADULT; AGED; BRAIN NEOPLASMS; DRUG EVALUATION, PRECLINICAL; EXOTOXINS; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, PARENTERAL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 10744219583     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026290315809     Document Type: Review

References (42)

1. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS: Cancer surveillance series [corrected]: Brain and other central nervous system cancers: Recent trends in incidence and mortality. J Natl Cancer Inst 91: 1382-1390, 1999
2. Howe WL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93: 824-842, 2001
3. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985
4. Dandy WE: Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA 90: 823-825, 1928
5. Imperato JP, Paleologos NA, Vick NA: Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818-822, 1990
6. Galanis E, Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer 82: 1371-1380, 2000
7. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572, 1999
8. Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang Q-C, Pai LH, Hendon J, Bigner DD: Intrathecal administration of single-chain immunotoxin, LMB-7 (B3(Fv)-PE38), produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci USA 93: 2765-2769, 1995
9. Pai LH, Pastan I: Immunotoxins and recombinant toxins. In: DeVita VT, Jr., Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer, 2nd edn, JB Lippincott Company, Philadelphia, 1995, pp 521-533
10. Pastan I: Targeted therapy of cancer with recombinant immunotoxins. Biochim Biophys Acta 1333: C1-6, 1997
11. Pastan I, FitzGerald D: Recombinant toxins for cancer treatment. [Review] [90 refs]. Science 254: 1173-1177, 1991
12. Phillips PC, Levow C, Catterall M, Colvin OM, Pastan I, Brem H: Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res 54: 1008-1015, 1994
13. Hall WA, Fodstad O: Immunotoxins and central nervous system neoplasia. J Neurosurg 76: 1-12, 1992
14. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247, 2001
15. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe S, Giardina S, Waldmann TA, Pastan I: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18: 1622-1636, 2000
16. LeMaistre CF, Craig FE, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T: Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 53: 3930-3934, 1993
17. LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J, Parker K, Shaw J, Deisseroth A, Woodworth T, Parkinson DR: Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79: 2547-2554, 1992
18. LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DR, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T: Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 337: 1124-1125, 1991
19. Kuzel TM, Rosen ST, Gordon LI, Winter J, Samuelson E, Kaul K, Roenigk HH, Nylen P, Woodworth T: Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: Efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk Lymphoma 11: 369-377, 1993
20. Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE: Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73: 1276-1285, 1994
21. Joshi BH, Kawakami K, Leland P, Puri RK: Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: Differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 8: 1948-1956, 2002
22. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157-2165, 2000
23. Pai LH, Bookman MA, Ozols RE, Young RC, Smith JW, Longo DL, Gould B, Frankel A, McClay EF, Howell S: Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer [see comments]. J Clin Oncol 9: 2095-2103, 1991
24. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I: Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nat Med 2: 350-353, 1996
25. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I: Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res 1: 859-864, 1995
26. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899-6903, 1987
27. Wickstrand CJ, Fung K-M, Trojanowski JQ, et al. Russell & Rubenstein's Pathology of Tumors of the Nervous System. Antibodies and Molecular Immunology: Immunohistochemistry and Antigens of Diagnostic Significance, 6th edn. Arnold: Oxford University Press, 1998, Vol 1
28. Humphrey PA, Wong AJ, Vogelstein B, Friedman HS, Werner MH, Bigner DD, Bigner SH: Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48: 2231-2238, 1988
29. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H: Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 44: 753-760, 1984
30. Torp SH, Helseth E, Dalen A, Unsgaard G: Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother 33: 61-64, 1991
31. Wikstrand CJ, Stenzel T, McLendon RE, Bigner DD: Correlation of EGFRwt RNA transcript levels and patient biopsy protein expression by immunohistochemistry. J Neuro-Oncol 2002 (in press)
32. Pastan I, Chaudhary V, FitzGerald DJ: Recombinant toxins as novel therapeutic agents. [Review] [155 refs]. Ann Rev Biochem 61: 331-354, 1992
33. Kunwar S, Pai LH, Pastan I: Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J Neurosurg 79: 569-576, 1993
34. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362-1368, 1997
35. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49: 2807-2813, 1989
36. Zalutsky MR, Moseley RP, Benjamin JC, Colapinto EV, Fuller GN, Coakham HP, Bigner DD: Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration. Cancer Res 50: 4105-4110, 1990
37. Bullard DE, Bourdon M, Bigner DD: Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain. J Neurosurg 61: 901-911, 1984
38. Bigner D, Brown M, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao X-G, Pegram CN, Wikstrand CJ, Herndon IJE, Vick NA, Paleologos NA, Cokgor I, Provenzale JM, Zalutsky MR: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16: 2202-2212, 1998
39. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076-2080, 1994
40. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL: High-flow microinfusion: Tissue penetration and pharmacodynamics. Am J Physiol 266: R292-R305, 1994
41. Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA, Koong SS, Cummins A, Paik CH, Oldfield EH: Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 87: 586-594, 1997
42. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-1029, 1995